Cover Image
市場調查報告書

抑鈣素基因系胜肽 (CGRP):開發中產品分析

Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 358694
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
抑鈣素基因系胜肽 (CGRP):開發中產品分析 Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 63 Pages
簡介

本報告提供全球各國治療抑鈣素基因系胜肽 (CGRP) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
    • 分析範圍
  • 抑鈣素基因系胜肽 (CGRP)的概要
  • 治療藥的開發
    • 臨床實驗中的產品:臨床實驗的各階段
    • 臨床實驗中的產品:各治療領域
    • 臨床實驗中的產品:不同症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的產品
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥途徑
    • 各分子類型
  • CGRP開發治療藥的企業
    • Alder Biopharmaceuticals Inc.
    • BCN Peptides, S.A.
    • Boehringer Ingelheim GmbH
    • Eli Lilly and Company
    • BCN Peptides, S.A.
    • Teva Pharmaceutical Industries Ltd.
    • Noxxon Pharma AG
  • 藥物簡介
    • ALD-403
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的進展
    • DD-04107
    • galcanezumab
    • NOXL-41
    • olcegepant
    • Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain
    • TEV-48125
  • 開發暫停的計劃
  • 開發中斷的計劃
  • 值得注意的最新趨勢·新聞稿 (全10件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1078TDB

Summary:

Calcitonin Gene Related Peptide (CGRP) - Calcitonin gene related peptide (CGRP) is a member of the calcitonin family of peptides. It exists in two forms alpha-CGRP and beta-CGRP. CGRP is produced in both peripheral and central neurons. CGRP is derived mainly from the cell bodies of motor neurons when synthesized in the ventral horn of the spinal cord and contribute to the regeneration of nervous tissue after injury. CGRP is derived from dorsal root ganglion when synthesized in the dorsal horn of the spinal cord and linked to the transmission of pain. CGRP also plays an important role in cardiovascular homeostasis and nociception.

Calcitonin Gene Related Peptide (CGRP) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 2, 2 and 2 respectively. Report covers products from therapy areas Central Nervous System which include indications Migraine, Cluster Headache Syndrome, Dental Pain, Inflammatory Pain, Osteoarthritis Pain and Pain.

The latest report Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2017, outlays comprehensive information on the Calcitonin Gene Related Peptide (CGRP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)
  • The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Calcitonin Gene Related Peptide (CGRP) - Overview
    • Calcitonin Gene Related Peptide (CGRP) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development
    • Alder Biopharmaceuticals Inc
    • Eli Lilly and Co
    • Serometrix LLC
    • Teva Pharmaceutical Industries Ltd
  • Calcitonin Gene Related Peptide (CGRP) - Drug Profiles
    • AFAP-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eptinezumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fremanezumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • galcanezumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXL-41 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CGRP for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Calcitonin Gene Related Peptide (CGRP) - Dormant Products
  • Calcitonin Gene Related Peptide (CGRP) - Discontinued Products
  • Calcitonin Gene Related Peptide (CGRP) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 17, 2017: Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA
      • Sep 09, 2017: Teva Showcases Data Demonstrating Potential of Fremanezumab to Address Significant Unmet Need in Patients with Chronic and Episodic Migraine
      • Sep 08, 2017: IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results For Up To 12 Months In Patients With Migraine
      • Sep 07, 2017: Alder BioPharmaceuticals to Present Data from Eptinezumab Development Program at 18th Congress of the International Headache Society
      • Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The International Headache Society
      • Sep 05, 2017: Teva to Present Fremanezumab Data on Migraine Prevention at the 18th Congress of the International Headache Society
      • Jun 27, 2017: Alder BioPharmaceuticals Announces Positive Eptinezumab Phase 3 Results for Prevention of Frequent Episodic Migraine
      • Jun 10, 2017: Lilly's Galcanezumab Significantly Reduces Number Of Migraine Headache Days For Patients With Migraine: New Results Presented At AHS
      • Jun 08, 2017: Lilly To Present Late-Breaking Data For Galcanezumab At The American Headache Society Annual Scientific Meeting
      • Jun 07, 2017: Alder to Present Migraine Prevention Data for Eptinezumab at 59th Annual Scientific Meeting of the American Headache Society
      • Jun 07, 2017: Teva's Fremanezumab Meets all Primary & Secondary Endpoints Across Both Monthly and Quarterly Dosing Regimens in Phase III Study in Episodic Migraine Prevention
      • May 31, 2017: Teva Announces Positive Results for Phase III Study of Fremanezumab for the Prevention of Chronic Migraine
      • May 12, 2017: Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine
      • Apr 28, 2017: Alder BioPharmaceuticals Presents Positive Phase 2b Study Data for Eptinezumab at 69th Annual American Academy of Neurology Meeting
      • Apr 24, 2017: Alder BioPharmaceuticals Presents Additional Data from Eptinezumab Development Program at 69th Annual American Academy of Neurology Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Alder Biopharmaceuticals Inc, H2 2017
  • Pipeline by Eli Lilly and Co, H2 2017
  • Pipeline by Serometrix LLC, H2 2017
  • Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top